# Alkermes plc (ALKS) Stock Analysis: A Strong Buy with 37% Potential Upside

- Link: https://www.directorstalkinterviews.com/alkermes-plc-alks-stock-analysis-a-strong-buy-with-37-potential-upside/4121241191
- Published: 2026-02-23T11:30:51+00:00
- Author: Madison Wilson

Individual investors eyeing opportunities in the biopharmaceutical sector may find
Alkermes plc (NASDAQ: ALKS) a compelling consideration. As a leading player in the
healthcare industry, Alkermes focuses on developing innovative treatments for neurological
and psychiatric conditions, addressing significant unmet medical needs. Headquartered
in Dublin, Ireland, the company boasts a market capitalization of $5.27 billion,
marking it as a substantial entity in the drug manufacturing landscape.

Currently trading at $31.91, Alkermes shares are near the midpoint of their 52-week
range of $26.13 to $35.52. The stock has shown resilience despite the recent price
change reflecting a neutral day of trading. The company’s performance metrics underscore
its growth trajectory, with revenue growth reported at 4.20% and a robust return
on equity of 22.35%. These figures demonstrate Alkermes’ ability to generate substantial
returns on shareholder investments, a promising indicator for potential investors.

Alkermes’ product portfolio is diverse, targeting conditions such as alcohol and
opioid dependence, schizophrenia, and bipolar I disorder. Its key marketed products,
including ARISTADA and VIVITROL, have positioned the company as a critical player
in the treatment of these complex health issues. Moreover, its pipeline of clinical
and preclinical candidates points to a continued commitment to innovation and expansion
in therapeutic offerings.

When evaluating the company’s valuation metrics, it’s essential to note the lack
of a trailing P/E ratio, which may be atypical but not uncommon for companies reinvesting
heavily in R&D to fuel future growth. However, the forward P/E of 16.47 suggests
the market anticipates earnings growth, aligning with the company’s strategic focus
on expanding its product offerings and market reach.

Investors should also consider the analyst ratings, which are overwhelmingly positive.
With 14 buy ratings and no sell ratings, the sentiment around Alkermes is notably
optimistic. The average target price sits at $43.81, indicating a potential upside
of approximately 37.30%. This substantial growth potential could be a significant
draw for investors looking to capitalize on stock appreciation.

From a technical perspective, Alkermes’ 50-day and 200-day moving averages stand
at $31.07 and $29.87, respectively, suggesting a stable upward trend. The Relative
Strength Index (RSI) at 40.29 implies that the stock is neither overbought nor oversold,
offering a balanced entry point for discerning investors. The MACD, a momentum indicator,
further supports the potential for a positive price movement, with a reading above
the signal line.

While Alkermes does not currently offer a dividend, the absence of a payout ratio
allows the company to reinvest profits into research and development, potentially
enhancing future shareholder value through capital gains. This strategic reinvestment
is pivotal for companies within the biopharmaceutical sector, where innovation drives
long-term success.

For investors seeking exposure to a company with a strong market position in a high-
demand industry, Alkermes presents a promising investment opportunity. Its solid
growth metrics, favorable analyst ratings, and strategic focus on developing treatments
for critical health conditions position it as a biopharmaceutical company with notable
upside potential. As the healthcare landscape continues to evolve, Alkermes’ commitment
to addressing complex medical needs could translate into significant returns for
its investors.

Share on: